免疫球蛋白恒定结构域作为基于 T 细胞受体的多发性骨髓瘤治疗靶点

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

对 T 细胞疗法耐药的多发性骨髓瘤细胞表现出 CD45+ 免疫逃逸表型

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.

多发性骨髓瘤中 T 细胞重定向疗法的可及性：患者、照护者与医生对认知和障碍的视角

Access to T-Cell Redirecting Therapies in Multiple Myeloma: Patient, Caregiver, and Physician Perspectives on Awareness and Barriers.

可编程工程菌调控代谢并原位重塑 TME 以增强过继性细胞治疗

Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.

多发性骨髓瘤免疫治疗序贯的真实世界证据：既往 GPRC5D 靶向治疗后 BCMA 靶向双特异性抗体可带来持久缓解

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5

靶向 BCMA 的双特异性抗体为经靶向 GPRC5D 的双特异性抗体治疗后进展的患者提供了一种有效且耐受性良好的治疗选择，支持该序贯方案作为一种有前景策略的可行性。

mRNA 疫苗在癌症免疫治疗中的应用：实体瘤和血液系统恶性肿瘤的当前进展与展望

mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.

工程化 TCR 导向的 T 细胞用于多发性骨髓瘤治疗

Engineering TCR-directed T-cells for the treatment of multiple myeloma.

靶向 IgA 和 IgG 表达型多发性骨髓瘤的 TCR T 细胞

TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

MDG1011（一种靶向 HLA-A*02:01 限制性 PRAME 抗原的 TCR-T 疗法）治疗高危髓系与淋系肿瘤的首次人体研究

First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.

入组 CD-TCR-001 I 期部分的患者，在所研究的少数患者中显示出 MDG1011 潜在临床和生物学活性的迹象。

急性髓系白血病 T 细胞受体治疗的最新进展

Current developments in T-cell receptor therapy for acute myeloid leukemia.